Guggenheim Maintains Buy on IQVIA Hldgs, Lowers Price Target to $234
Guggenheim analyst Sandy Draper maintains IQVIA Hldgs (NYSE:IQV) with a Buy and lowers the price target from $246 to $234.
Barclays Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $215
Barclays analyst Luke Sergott maintains IQVIA Hldgs (NYSE:IQV) with a Overweight and lowers the price target from $235 to $215.
Expert Ratings for IQVIA Hldgs
Analysts have provided the following ratings for IQVIA Hldgs (NYSE:IQV) within the last quarter:
6 Analysts Have This to Say About IQVIA Hldgs
Analysts have provided the following ratings for IQVIA Hldgs (NYSE:IQV) within the last quarter:
Barclays Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $235
Barclays analyst Luke Sergott maintains IQVIA Hldgs (NYSE:IQV) with a Overweight and lowers the price target from $255 to $235.
IQVIA Study Demonstrates Cost And Time Savings Of Decentralized Trials
The study found faster, less expensive, and more engaging trials can be achieved using tech-enabled decentralized clinical trial models